SHOC2 acts as a strong synthetic lethal interactor with MEK inhibitors in multiple KRAS cancer cell lines. SHOC2 forms a heterotrimeric complex with MRAS and PP1C that is essential for regulating RAF and MAPK-pathway activation by dephosphorylating a specific phosphoserine on RAF kinases. Here we present the high-resolution crystal structure of SHOC2-MRAS-PP1C (SMP) complex and apo-SHOC2. Our structures reveal that SHOC2, MRAS and PP1C form a stable ternary complex where all three proteins synergistically interact with each other. Our results show that dephosphorylation of RAF substrates by PP1C is enhanced upon interacting with SHOC2 and MRAS. The SMP complex only forms when MRAS is in an active state and is dependent on SHOC2 functioning as a scaffolding protein in the complex by bringing PP1C and MRAS together. Our results provide structural insights into the role of the SMP complex in RAF activation, how mutations found in Noonan syndrome enhance the complex formation and reveal new avenues for therapeutic interventions.C. elegans as a positive modulator of the MAPK pathway 12,13 . It is a ubiquitously expressed protein composed primarily of predicted leucine-rich repeats (LRRs). N-terminal to the LRR domains, SHOC2 contains a ~90-residue long sequence that is predicted to be intrinsically disordered and has been suggested to be necessary for complex formation with MRAS and PP1C 11,14 . Germline mutations in SHOC2 (S2G, M173I, and Q269H/H270Y) have been detected in NS 11,[15][16][17] . SHOC2 plays a vital role in transformation, metastasis, epithelial-tomesenchymal transition, and MAPK pathway inhibitor resistance [18][19][20][21] . Multiple genome-scale, single-gene CRISPR/Cas9 fitness screens in human cancer cells have suggested selective dependency of RAS mutant cells on SHOC2 20,[22][23][24] . SHOC2 was also identified as the strongest synthetic lethal target in the presence of MEK inhibitors in KRAS mutant lung and pancreatic cancer cell lines 19 . Thus, SHOC2 may provide a unique therapeutic opportunity within the RTK-RAS-MAPK pathway in oncogenic RAS cells.The SMP complex formation is initiated following MRAS activation as SHOC2 and PP1C bind only to MRAS-GTP 25 . The canonical RAS family members HRAS, KRAS, and NRAS, also bind SHOC2, although with considerably lower affinity than MRAS 26 . The nature of the selectivity for MRAS is not known. MRAS shares ~50% sequence identity with the canonical RAS proteins and contains an extra ten amino acids at the N-terminus. Activating mutations in MRAS are very rare in cancer; however, gain-of-function mutations (G23V, T68I, Q71R) in MRAS have been identified in NS patients 27,28 . In the SMP complex, PP1C provides the enzymatic activity for dephosphorylation. PP1C is a class of serine/threonine phosphatases with three highly conserved isoforms (PP1CA, PP1CB, and PP1CC with >90% sequence identity) that are ubiquitously expressed and catalyze the dephosphorylation of a substantial fraction of phosphoserine/threonine in all eukaryotic cells [29][30][31] . Mutation...